Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane

Equality Impact Assessment (Guidance development) (PDF 235 KB)

Final appraisal determination

Final appraisal determination document (PDF 549 KB)

Committee papers (PDF 2.66 MB)

Public committee slides (PDF 255 KB)

Draft guidance: 1

Appraisal consultation document (PDF 527 KB)

Committee papers (PDF 3.75 MB)

Final scope (PDF 99 KB)

Final matrix (PDF 97 KB)

Equality Impact Assessment (Guidance development) TA371 22 December 2015 (PDF 167 KB)

Committee papers TA371 17 November 2015 (PDF 556 KB)

Final appraisal determination document TA371 17 November 2015 (PDF 448 KB)

Consultation document TA371 08 October 2014 (PDF 202 KB)

Consultation document TA371 08 October 2014 (PDF 159 KB)

Consultation document TA371 08 October 2014 (PDF 257 KB)

Consultation document TA371 02 December 2014 (PDF 252 KB)

Consultation document TA371 08 October 2014 (PDF 418 KB)

Final appraisal determination document TA371 08 August 2014 (PDF 1.98 MB)

Consultation document TA371 08 August 2014 (PDF 416 KB)

Consultation document TA371 23 April 2014 (PDF 6.49 MB)

Equality impact assessment (Scoping) ID371 22 October 2013 (PDF 117 KB)

Final scope TA371 22 October 2013 (PDF 99 KB)

Final matrix TA371 22 October 2013 (PDF 100 KB)

NICE's response to comments on the draft scope and provisional matrix TA371 22 October 2013 (PDF 126 KB)

Final scope Draft Scope (pre-referral) ID371 04 April 2013 (PDF 104 KB)

Provisional matrix (pre-referral) TA371 04 April 2013 (PDF 98 KB)